Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Jopaul MathewDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.ORCID 0000-0002-4712-1403
Bo ZhouDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.ORCID 0009-0001-5603-4221
Reagan S HaneyDepartment of Biochemistry and Molecular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, 120 E. Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-2452-4103
Kevin A KunzDepartment of Pharmaceutical Sciences, University of Illinois Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States.ORCID 0009-0007-7427-8485
Leticia S Do AmaralDepartment of Biochemistry and Molecular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, 120 E. Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-2861-216X
Rudraneel Roy ChowdhuryDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.
Joshua H ButlerDepartment of Biochemistry and Molecular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, 120 E. Green Street, Athens, Georgia 30602, United States.
Haibo LiDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.
Amarraj J ChakrabortyDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.
Anika TabassumDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.ORCID 0000-0001-5723-5896
Emily K BremersDepartment of Biochemistry and Molecular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, 120 E. Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-9768-0211
Emilio F MerinoDepartment of Biochemistry and Molecular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, 120 E. Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-5400-7377
Marcus C S LeeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, U.K.
Delphine BaudMedicines for Malaria Venture, Geneva 1215, Switzerland.
Stephen BrandMedicines for Malaria Venture, Geneva 1215, Switzerland.
Maxim TotrovMolsoft LLC, 11999 Sorrento Valley Road, San Diego, California 92121, United States.ORCID 0000-0001-8594-274X
Maria Belen CasseraDepartment of Biochemistry and Molecular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, 120 E. Green Street, Athens, Georgia 30602, United States.ORCID 0000-0001-6341-3169
Paul R CarlierDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.ORCID 0000-0002-6683-285X
Funding
Training in Tropical and Emerging Global Diseases - SupplementT32AI060546 · NIAID · UNIVERSITY OF GEORGIA (UGA) · PI Silvia N Moreno, Vasant Muralidharan · 2004 to 2026
$5.1M
Optimization of antimalarials targeting multiple life stages of the parasiteR01AI157445 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Paul R Carlier, Maria Belen Cassera · 2021 to 2026
$4.5M
PREP at University of GeorgiaR25GM109435 · NIGMS · UNIVERSITY OF GEORGIA · PI DOLAN, ERIN L, KLONOWSKI, KIMBERLY D. · 2014 to 2024
The development of parasite resistance to both artemisinin derivatives and their partner drugs jeopardizes the effectiveness of the artemisinin combination therapy. Thus, the discovery of new antimalarial drugs, with new mechanisms of action, is urgently needed. We recently disclosed that β-carboline
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
β-Carboline-3-carboxamide Antimalarials: Structure-Activity Relationship, ADME-Tox Studies, and Resistance Profiling. · full record | Socratic